Rossignol DP - Search Results

1

Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers.

Rossignol DP, Wasan KM, Choo E, Yau E, Wong N, Rose J, Moran J, Lynn M. Rossignol DP, et al. Antimicrob Agents Chemother. 2004 Sep;48(9):3233-40. doi: 10.1128/AAC.48.9.3233-3240.2004. Antimicrob Agents Chemother. 2004. PMID: 15328078 Free PMC article.

2

Safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study.

Wong YN, Rossignol D, Rose JR, Kao R, Carter A, Lynn M. Wong YN, et al. J Clin Pharmacol. 2003 Jul;43(7):735-42. J Clin Pharmacol. 2003. PMID: 12856387 Clinical Trial.

3

Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue.

Rossignol DP, Lynn M. Rossignol DP, et al. J Endotoxin Res. 2002;8(6):483-8. doi: 10.1179/096805102125001127. J Endotoxin Res. 2002. PMID: 12697095

4

Association of the endotoxin antagonist E5564 with high-density lipoproteins in vitro: dependence on low-density and triglyceride-rich lipoprotein concentrations.

Wasan KM, Sivak O, Cote RA, MacInnes AI, Boulanger KD, Lynn M, Christ WJ, Hawkins LD, Rossignol DP. Wasan KM, et al. Among authors: rossignol dp. Antimicrob Agents Chemother. 2003 Sep;47(9):2796-803. doi: 10.1128/AAC.47.9.2796-2803.2003. Antimicrob Agents Chemother. 2003. PMID: 12936976 Free PMC article.

5

Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia [corrected].

Lynn M, Wong YN, Wheeler JL, Kao RJ, Perdomo CA, Noveck R, Vargas R, D'Angelo T, Gotzkowsky S, McMahon FG, Wasan KM, Rossignol DP. Lynn M, et al. Among authors: rossignol dp. J Pharmacol Exp Ther. 2004 Jan;308(1):175-81. doi: 10.1124/jpet.103.056531. Epub 2003 Oct 17. J Pharmacol Exp Ther. 2004. PMID: 14566003 Clinical Trial.

6

Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers.

Rossignol DP, Wong N, Noveck R, Lynn M. Rossignol DP, et al. Innate Immun. 2008 Dec;14(6):383-94. doi: 10.1177/1753425908099173. Innate Immun. 2008. PMID: 19039062 Free article.

7

Lipoprotein distribution of a novel endotoxin antagonist, E5531, in plasma from human subjects with various lipid levels.

Wasan KM, Strobel FW, Parrott SC, Lynn M, Christ WJ, Hawkins LD, Rossignol DP. Wasan KM, et al. Among authors: rossignol dp. Antimicrob Agents Chemother. 1999 Oct;43(10):2562-4. doi: 10.1128/AAC.43.10.2562. Antimicrob Agents Chemother. 1999. PMID: 10508046 Free PMC article.

8

Consequences of interaction of a lipophilic endotoxin antagonist with plasma lipoproteins.

Rose JR, Mullarkey MA, Christ WJ, Hawkins LD, Lynn M, Kishi Y, Wasan KM, Peteherych K, Rossignol DP. Rose JR, et al. Among authors: rossignol dp. Antimicrob Agents Chemother. 2000 Mar;44(3):504-10. doi: 10.1128/AAC.44.3.504-510.2000. Antimicrob Agents Chemother. 2000. PMID: 10681310 Free PMC article.

9

Deactivation of the lipopolysaccharide antagonist eritoran (E5564) by high-density lipoprotein-associated apolipoproteins.

Fleischer JG, Rossignol D, Francis GA, Chan T, Lynn M, Wasan KM. Fleischer JG, et al. Innate Immun. 2012 Feb;18(1):171-8. doi: 10.1177/1753425910394395. Epub 2011 Mar 7. Innate Immun. 2012. PMID: 21382909 Free article.

10

TLR4 antagonists for endotoxemia and beyond.

Rossignol DP, Lynn M. Rossignol DP, et al. Curr Opin Investig Drugs. 2005 May;6(5):496-502. Curr Opin Investig Drugs. 2005. PMID: 15912963 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

43 results

Search Page

Filters